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Development and Progress of Engineering
of Skeletal Muscle Tissue
Hua Liao, M.D.,1 and Guang-Qian Zhou, Ph.D.2,3
Engineering skeletal muscle tissue remains still a challenge, and numerous studies have indicated that this
technique may be of great importance in medicine in the near future. This article reviews some of the recent
findings resulting from tissue engineering science related to the contractile behavior and the phenotypes of
muscle tissue cells in different three-dimensional environment, and discusses how tissue engineering could be
used to create and regenerate skeletal muscle, as well as the extended applications and the related patents
concerned with engineered skeletal muscle.
Introduction
Tissue engineering represents a scientific approachthat attempts to mimic neoorganogenesis.1 In contrast to
the transplantation of donor organs, tissue engineering starts
with cultured proliferating cells and aims at reconstituting a
tissue-like structure in culture. Regenerating or engineering
new tissues may be a potential solution for the replacement of
lost, damaged, or failing tissues and organs in general1,2;
therefore, many investigations have been developed and at-
tempted to regenerate human tissues that have recently en-
tered into clinical practice in the case of tissues such as skin,
bone, and cartilage.3–8 Further, the creation of skeletal mus-
cle tissue using tissue engineering methods holds promise for
the treatment of a variety of muscle diseases, including skel-
etal myopathies such as muscular dystrophy or spinal mus-
cular atrophy9,10; in addition, traumatic injury, aggressive
tumor ablation, and prolonged denervation are common
clinical situations that often result in significant loss of muscle
tissue and require subsequent surgical reconstruction. En-
gineering skeletal muscle tissue remains still a challenge, and
numerous studies have indicated that these techniques may
be of great importance in medicine in the near future, while
several reviews have summarized those construct techniques
and described the development of muscle engineering.11–13 In
this article, we review some of the recent findings resulting
from tissue engineering science related to the contractile be-
havior and the phenotypes of muscle tissue cells in different
three-dimensional (3D) environment and discuss how tissue
engineering could be used to create and regenerate skeletal
muscle, as well as the extended applications and the related
patents with engineered skeletal muscle.
Engineering Skeletal Muscle Tissue
According to the structure and function of skeletal muscle,
the requirements of engineered muscle are as follows: re-
constructed muscle is a parallel alignment of myofibrils with
myosin=actin filaments, intracellular calcium storage, and
acetylcholine receptors, which are needed for creating direct
forces and functional use. The neotissue must be biocom-
patible, must integrate and regenerate lost muscle tissue, and
needs to be vascularized and innervated.14 Khodabukus
et al.11 further points out that for engineered muscle to func-
tion as an effective model for the study of muscle physiology
and function, it needs to satisfy some criteria. First, there
needs to be a fast, easy, and standardized technique for en-
gineering muscle. Second, it needs to be possible to engineer
the tissue from transformed skeletal muscle cells such as
C2C12s to decrease the variability of primary cell isolation
and to allow for stable mutations to be made for testing gene
function. Third, the physiology and function of the tis-
sue need to be readily testable. Fourth, the model needs to be
able to reproduce the effects of exercise=developmental
stimuli. Fifth, the model needs to use standard, easy-to-use,
and relatively inexpensive machines so that neither the cost
nor the complexity of the engineering prevents investigators
from being able to use the system.
Two general approaches are adopted to engineer artificial
skeletal muscle tissue. One way is to regenerate autologous
satellite cells by biopsy, expand and differentiate cells in a 3D
defined environment in vitro in an artificial bioreactor, and
reimplant the neotissue after differentiation has taken place
(in vitro tissue engineering).14–16 The second approach in-
volves the generation of satellite cells, expansion of cells
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in vitro, and reimplantation of donor cells using a transport
matrix, which allows differentiation into myotubes in vivo to
occur (myoblast transfer therapy). Implanted myoblasts
might serve as vehicles for the delivery of recombinant
proteins (in vivo tissue engineering).14–16
The first reported 3D engineered skeletal muscle seeded
partially differentiated primary avian myoblasts within a
collagen gel matrix atop a stainless steel mesh or a flat ny-
lon ring attached to the bottom of the dish.17 Unlike two-
dimensional primary avian myoblast monolayers that detach
after 5–6 days in culture, the embedded cells could be
maintained for 3–4 weeks as a ‘‘floating sheet’’ of myotubes
suspended above the culture dish under constant mechanical
tension as a result of their attachment to either the nylon ring
or steel mesh (Fig. 1A). As a result of the extended time in
culture, the embedded cultures contained higher levels of
protein, including myosin heavy chain (MHC), DNA, and a
higher ratio of protein–DNA.17 Further, the embedded cul-
tures showed the formation of neonatal-like myofibers with
characteristics such as a well-developed basal lamina, well-
organized contractile machinery, and peripherally located
myonuclei.
Many researchers use the cells-in-gel technique developed
simultaneously in the Matsuda and Vandenburgh’ laborato-
ries18,19 to replace the embeddedmonolayer technique. In this
technique, myoblasts were mixed with an extracellular matrix
(ECM) solution (collagen I or Matrigel), and then transferred
to a mold and allowed to set.18–20 After a few days in culture,
the medium was changed to promote the fusion and differ-
entiation of the myoblasts (Fig. 1B). This technique decreased
the culture work before the formation of constructs and had
the increased flexibility of using molds of any shape. How-
ever, when the diameter of the construct was greater than
500 mm, the core of the muscle became necrotic.18 The cells-
in-gel technique is very effective for producing a gene deliv-
ery system,19 but there have been no reports on the ability of
these constructs to produce forcewhen electrically stimulated.
The specific force (force=tissue cross-sectional area) of cells-in-
gel constructs is quite low because of the amount of scaffold
required and the resulting inhibition of muscle cell fusion.
However, the low-specific force makes it difficult to interpret
the functional relevance of these tissues.
The novel technique for engineering 3D muscle uses self-
organization of a muscle cell monolayer. Strohman and col-
leagues21 in 1990 reported first that primary skeletal muscle
cells could form a 3D construct in the absence of an external
scaffold. In this report, the authors grew primary myoblasts
on a membrane of Saran Wrap held in place using steel pins
fixed in a layer of Sylgard (polydime-thylsiloxane). As the
muscle cells differentiated, their contractile activity caused
the monolayer to detach from the membrane and rolled into
a starfish-shaped structure held in tension by cellular adhe-
sion to the stainless steel pins. As the myotubes reorganized
into a 3D structure, the normal connective tissue layers, epi-
mysium, perimysium, and endomysium, were produced by
the fibroblasts in the culture (Fig. 1C). Like the other mod-
els, these muscle constructs expressed more developmen-
tally mature MHCs than observed in monolayers.21 The
Dennis laboratory used the observations made by Strohman
and his colleagues21 to develop a repeatable technique for
engineering 3D skeletal muscle tissue for the study of the
functional development of muscle.22,23 In place of the Saran
Wrap, laminin-coated Sylgard plates were used. The laminin
promoted cell adhesion and mobility, whereas the Sylgard
allowed the attachment of two sutures to the dish. After the
myoblasts differentiated and began to contract, they de-
tached from the plate and reorganized into a cylindrical
structure using the sutures as tendon-like anchors.22 This
structure was morphologically similar to skeletal muscle
in vivo displaying individual fibers in a loose sarcomeric
array. Although the presence of myoblasts was necessary for
the development of contractile tissue, fibroblasts and the
ECM they produced were essential to the formation of the
3D tissues. The 3D muscle tissue produced in this manner,
termed Myooids, contracted spontaneously producing ap-
proximately 25mN of force. The Myooids can be generated
from a standardized technique from either primary cells or a
coculture of C2C12 and NIH 3T3 cells, and their physiology
and function were readily testable. However, Myooids took
approximately 35 days to form in culture, and a source of
fibroblasts was required for tissue formation.22,23
To address these concerns, Huang et al.24,25 developed a
modified method to engineer self-organized 3D engineered
muscles. In place of the fibroblasts and laminin, they used a
biodegradable gel of fibrin. Muscle cells were plated on a thin
film of fibrin where they proliferated and then fused to form
myotubes. As with the Myooids, the cells contracted the gel
around two anchors that can be removed from the substrate
for testing or mechanical interventions. The primary differ-
ences between fibrin constructs and Myooids are that they
form in 7–10days, they can bemade in the complete absence of
fibroblasts, and they produce twice asmuch active force as the
Myooids. They also performed the generation of engineered
muscles from C2C12 cells.24,25 These constructs produced
approximately the same amount of force as Myooids and can
survive in culture for upward of 3 weeks. Cells can be cul-
tured for a sufficient time to permit the study of long-term
changes in muscle phenotype or function.
The composition of the ECM plays an essential role in
the attachment, alignment, and differentiation of myoblasts,
while the ECM also provides a framework for cell adhesion
and tissue growth, which promotes cell proliferation and
differentiation.26,27 Many researchers put their eyes on spe-
cial biomaterials with the same internal structures as skeletal
muscle matrix, which are biocompatible and bioresorbable,
and maybe the replace of ECM of skeletal muscle tissue
in vitro. The matrices used in muscle tissue engineering can
be divided into synthetic and biologically derived biomate-
rials, which are cocultured with myoblasts usually in vitro
(Fig. 1D). Saxena et al.28 placed myoblasts onto polyglycolic
acid (PGA) meshes and transplanted them in vivo. After 6
weeks, a vascularized muscle-like tissue could be seen. Some
investigators established in vitro cell cultures cultivating
muscle cells in Matrigel. However, Matrigel, an extract from
the Engelbreth-Holm-Swarm mouse sarcoma, contains vari-
ous ECM proteins and growth factors in undefined concen-
trations. It has the ability to change gene expression in cells
and promotes differentiation into myoblasts. It has been used
in combination with collagen as a 3D scaffold, but because of
its origin it is suitable only for experimental models and not
for clinical use.29
It has been shown that biological materials can support
in vivo and in vitro cell adhesion and proliferation. Acellular
matrices, which have been remodeled in living tissues and
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can function as bladder, urethra, and small bowel substi-
tutes,30–32 are also explored about its possibility of being the
biological muscle tissue scaffold. Moreover, in vivo evolution
after transplantation of acellular constructs is inspiring, and
few skeletal muscle tissue engineering studies have reported
on successful generation of living tissue substitutes for func-
tional skeletal muscle replacement. There are several potential
advantages to using acellular tissue as a scaffold for pro-
ducing engineered muscle constructs. First, the process to
remove cells renders the tissue not only acellular but also
nonimmunogenic. Engineeredmuscle constructs designed for
use in vivomust be capable of force production and must also
FIG. 1. Different methods for engineering skeletal muscle tissue. (A) Floating collagen sheet of myotubes; (B) the casting
extracellular matrix involving myotubes; (C) self-organized 3D engineered muscles; (D) cocultured myoblasts with specific
biomaterials.
(Fig. 1. continued ?)
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be immunologically inert. Second, the remnant neural path-
ways through the acellularized tissue scaffold may facilitate
the incorporation of peripheral nerves into the acellular con-
structs, promoting innervation. Third, it may be possible to
use the remnant ECM from the native vascular system in
acellular skeletal muscle to perfuse the constructs, allowing
them to grow larger, produce more force, and reestablish a
fully recellularized vascular bed. In addition, the use of acel-
lular muscle may allow maintenance of a construct’s size and
shape after implantation. Further, the retained ECM proteins
and residual endomysial tubes may enhance incorporation of
such a construct in vivo.33 The members of Conconi group34,35
cultured myoblasts from rat flexor digitorum brevis, har-
vested, and seeded on patches of homologous acellular ma-
trix, obtained by detergent-enzymatic treatment of abdominal
muscle fragments. Myoblast-seeded patches were trans-
planted to repair obliqui abdominis muscles, which showed
well-preserved muscle structure, abundant blood vessels and
myoblasts, and electromyography evidenced in them single
motor-unit potentials about 9 days. This cell–matrix con-
structs were also used to repair a full-thickness defect of ab-
dominal wall of female Lewis rats. The result showed that the
implants appearedwell preserved, were integrated in the host
tissue, and maintained their original dimension and thickness
until 9 months, as demonstrated by the expression of SrY
mRNA and by the presence of Y chromosome probe signal.35
The authors concluded that autologous myoblast–homolo-
gous acellular muscle matrix constructs were a promising tool
for body-wall defect repair, because they were in vivo re-
populated by skeletal muscle fibers and nervous system ele-
ments and maintained their structural integrity, following the
host development.
Collagens and alginate hydrogels have been used to replace
the ECM in vitro, to enhance the attachment of myoblasts, or
to alter their growth.27,36,37 However, these matrices are not
biodegradable, and some are potentially immunogenic.38,39
Because in vitro skeletal muscle tissue engineering involves
culturing isolated primary myoblasts in an environment
leading to the formation of a 3D tissue construct, idealmatrices
for such an approach should provide a high surface area for
cell–matrix interactions, sufficient space for ECM generation,
and a minimal diffusion barrier during in vitro culture.40,41
Moreover, the matrix should be resorbable once it has served
its purpose of providing a primary structure for the develop-
ing tissue.38,42 Fibrin possesses the above-mentioned fea-
tures, and it is an ideal cell culture matrix42,43; therefore, Bach
et al.44–46 developed a 3D fibrin matrix seeded with myoblasts.
They focused on myogenic transcription factors, such as MyoD
andMyogenin, and the acetylcholine receptor, and proved that
the fibrin 3D matrix was the structural basis and the promoter
of cell survival, proliferation, and cell organization. Thus, it
served not only as a 3D structure for the culture system but
offered essential additional biologic properties. Myoblasts can
proliferate and fuse to myotubes in the 3D fibrin matrix.
Recently, new polymer biomaterials are followed interest
by muscle engineering researchers. Williamson et al.47 pro-
duced poly(e-caprolactone) (PCL) fibers by wet spinning from
solutions in acetone under low shear (gravity flow) conditions.
This gravity spun polycaprolactone fibers were used to con-
struct muscle tissue adopting fibroblasts and myoblasts in cell
culture. They obtained engineered muscle using this gravity-
spun PCL fibers for 3D scaffold production. Masuko et al.48
adopted another scaffold, chitosan-peptide complex based on
the selective reaction of chitosan with 2-iminothiolane, to en-
gineer skeletal muscle tissue in vitro. Shah et al.49 investigated
the use of phosphate-based glass fibers as a potential scaffold
material for the in vitro engineering of craniofacial skeletal
muscle. They used human masseter–derived cell cultures to
seed the glass fibers, which were arranged into various con-
figurations. Growth factors andmatrix components were used
to manipulate the in vitro environment. Outcome was deter-
mined with the aid of microscopy, time-lapse footage, im-
munofluorescence imaging, and CyQUANT proliferation,
creatine kinase, and protein assays. They concluded that a
3D mesh arrangement of the glass fibers was the best at en-
couraging cell attachment and proliferation. In addition, in-
creasing the density of the seeded cells and using Matrigel
and insulin-like growth factor I enhanced the formation of
prototypic muscle fibers. Considering that skeletal muscle
consists of parallel bundles of myotubes formed by the fusion
of myoblasts, Huang et al.50 fabricated nanofibrous and mi-
cropatterned polymers as cell culture substrates to guide the
morphogenesis of muscular tissue. The nanoscale and micro-
scale topographic features regulated cell and cytoskeleton
alignment, myotube assembly, myotube striation, and myo-
blast proliferation. This bottom-up approach from nanoscale
to tissue level demonstrated the potential of nanofibrous
polymers for engineering the assembly of cell and tissue
structure. Riboldi et al.51 investigated the suitability, as scaffold
for skeletal muscle tissue engineering, of a known biodegrad-
able block copolymer (DegraPols) processed by electrospin-
ning in the novel form of microfibrous membranes. The
scaffolds were characterized with reference to their mor-
phological, degradative, and mechanical properties. Subse-
quently, cell viability, adhesion, and differentiation on coated
and uncoated DegraPols slides were investigated using line
cells (C2C12 and L6) and primary human satellite cells. The
membranes exhibited absence of toxic residuals and satisfac-
torymechanical properties. A promising cellular responsewas
also found in their preliminary experiments. Positive staining
for MHC expression indicated that differentiation of C2C12-
multinucleated cells occurred within the porous elastomeric
substrate. The author regarded the suitability of electrospun
DegraPols membranes as scaffolds for skeletal muscle tissue
engineering, which represented a promising alternative to
scaffolds currently used in this field.
In 2006, Lam et al.52 reported alignment of prefused and
differentiated skeletal muscle cells in vitro by use of continu-
ous micropatterned wavy silicone surfaces, with features
sized 3, 6, and 12mm in periodicity. Wave features with 6mm
periodicity produced the most healthy, aligned myoblasts.
Alignment was found to be a function of plating density.
Further growth on these substrates with aligned myoblasts
promoted fusion, yielding healthy aligned myotubes. They
thought that method will be useful for applications in which
differentiated myogenic cells need to be aligned unidirec-
tionally as in the development of engineered muscle. At
present, the modified scaffolds were developed and applied
extensively in muscle tissue engineering field. For example,
Boontheekul and Mooney53 took selected controlled degra-
dation alginate scaffold as a delivery vehicle for skeletal
muscle tissue engineering; Huber et al.54 used electrospun,
parallel aligned nylon 6=6 microfiber arrays for the cul-
ture of C2C12 myoblasts and their differentiation to form
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mechanically stable, orientated myotubes in vitro. Yan et al.55
adopted a novel technique. They constructed a multilayered
culture of skeletal muscle cells, derived from neonatal satel-
lite cells, using polarized matrix of type I collagen fibrils that
were distributed in a 3D pattern of organization that mim-
icked many of the features of intact tissue. These multilayered
cultures were composed of elongated multinucleated myo-
tubes that were MyoD positive. Histological studies indicated
that the multiple layers of myotubes can be distinguished.
Expression of muscle-specific markers such as MHC, Dys-
trophin, integrin alpha-7, alpha-enolase, and beta-enolase
was detected at levels near adult values, while physiological
measurements of the engineered skeletal muscle showed that
they tetanized and displayed physiologic force length be-
havior, although developed force per cross-sectional area
was below that of native rat skeletal muscle. In 2008, the
miniature bioartificial muscles were produced by tissue en-
gineering skeletal muscle myoblasts into 3D muscle with
parallel myofibers attached to two flexible microposts, which
acting as artificial tendons in a 96-well plate format in the
lab of Vandenburg et al.56 They adopted Sylgard 184 to cast
7-mm-diameter, 6-mm-deep wells with flexible attachment
microposts of varying diameters (300–800 mm), 4–5mm tall,
and 4mm apart. Miniature bioartificial muscles generated
tetanic (active) forces upon electrical stimulation measured
with a novel image-based motion detection system. Choi
et al.57 examined the feasibility of using PCL=collagen-based
nanofibers using electrospinning as a scaffold system for im-
plantable engineered muscle. Their aligned composite nano-
fiber scaffolds seeded with skeletal muscle cells provided
implantable functional muscle tissues for patients with large
muscle defects. Kroehne et al.58 described the application of
artificial scaffolds (collagen sponges [CS]) consisting of col-
lagen-I with parallel pores (width 20–50 mm) using the per-
manent myogenic cell line C2C12. CS were infiltrated with
a high-density cell suspension, incubated in medium for
proliferation of myoblasts before further culture in fusion
medium to induce differentiation and formation of multinu-
cleated myotubes. The biodegradable CS with parallel pores
supported the formation of oriented muscle fibers, and
formed in situwith host contributions in the outer portions of
the regenerates 14–50 days after surgery when the constructs
were grafted into the beds of excised anterior tibial muscles of
immunodeficient host mice. Propst et al. model system com-
bined a novel aligned collagen tube and autologous skeletal
muscle satellite cells to create an engineered tissue repair for a
surgically created ventral hernia. They observed the signifi-
cant persistence of transplanted skeletal muscle cell mass
within the engineered repair, the integration of new tissue
with adjacent native muscle, and the presence of significant
neovascularization.59
Loading, Testing, and Applying
of the Engineered Muscle Tissues
There have been several attempts to induce fusion of
myoblasts to myotubes in vitro, imitating the in vivo condi-
tions during myogenesis. Mechanical stimulation is one
important factor during myogenesis that influences gene
expression, protein synthesis, and total RNA=DNA con-
tent.60–62 The parallel alignment of myotubes can be induced
by stretch stimulation.63 It has been shown that mechanical
forces also have an important impact on mature skeletal
muscle on myofiber diameter, cell number, and myofiber
composition. Vandenburg and Kaufman64 are the first to
demonstrate that stretch of muscle cells in vitro could be used
to model hypertrophy in vivo. After cyclic stretch, the rate of
amino acid uptake, protein synthesis, and the total protein
isolated all increased. Baar et al. used a similar model to
show that stretch of myotubes in vitro resulted in an increase
in the ribosomal S6 protein kinase (S6K1) activity, potentially
connecting myotube stretch to the increase in protein syn-
thesis.65 Two reports have shown that stretching 3D en-
gineered skeletal muscles also has similar effects to exercise
in vivo.20,62 Cheema and colleagues20 had shown that the
stretch of engineered muscles resulted in increased produc-
tion of mechanogrowth factor similar to resistance exercise.
Powell et al. improved the development of 3D human skel-
etal muscle tissue using collagen and Matrigel as 3D scaffold
by mechanical stimulation.62 Other studies focusing on the
in vitro creation of skeletal muscle showed a different mor-
phologic and functional appearance without mechanical
stimulation in comparison to native skeletal muscle. Matsu-
moto et al.66 showed that the simple application of a con-
tinuous strain to a fibrin gel facilitated the development of
fibril alignment and bundle-like structures in the fibrin gel
in the direction of the applied strain. Myoblasts cultured in
this gel also exhibited well-aligned cell patterning in a di-
rection parallel to the direction of the strain. Interestingly, the
direction of cell proliferation was identical to that of cell
alignment. Finally, the oriented cells formed linear groups
that were aligned parallel to the direction of the strain and
replicated the native skeletal muscle cell patterning. In ad-
dition, vein endothelial cells formed a linear, aligned vessel-
like structure in this system.
Because ECM content was significantly higher, myofiber
density was low, and maturation was incomplete without
stimulation for engineeredmuscle,14,67 the in vitro regenerated
skeletal muscle tissue could achieve only 1% to 2% of forces of
native skeletal muscle.22,23,67 To improve the ratio of muscle
fibers and ECM, Powell et al.62 created a mechanical cell
stimulator that was able to stretch and relax the cell cultures
in vitro, involving a force transducer measuring passive forces
and viscoelastic properties. The mechanical stimulation im-
proved the structure of the engineered skeletal muscle by
increasing the mean myofiber diameter, the elasticity, and the
myofiber area percentage. However, the tissue that resulted
was not an appropriate substitute for functional implanta-
tion, although this neotissue came closer to skeletal muscle
than other attempts. Computerized mechanical application of
mechanical forces to differentiating skeletal muscle myoblasts
in vitro generated 3D artificial muscle organs.68 These organs
contained parallel networks of long unbranched myofibers
organized into fascicle-like structures. Tendon development
was initiated, and the muscles were capable of performing
directed, functional work. This kinetically engineered organs
provided a new method for studying the growth and devel-
opment of normal and diseased tissue.68 The mechanical
and mechano-molecular responses were further detected by
Brady et al.69 on their tissue-engineered muscle 3D collagen
construct adopting primary human skeletal muscle cells,
masseter muscle biopsies. In 2008, Moon du et al.70 described
an in vitro preconditioning protocol that improved the con-
tractility of engineered skeletal muscle after implantation
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in vivo. In their work, primary human muscle precursor cells
(MPCs) were seeded onto collagen-based acellular tissue scaf-
folds and subjected to cyclic strain in a computer-controlled
bioreactor system. Bioreactor preconditioning produced via-
ble muscle tissue constructs with unidirectional orientation
and contractile responses. This MPC-seeded constructs pre-
conditioned in the bioreactor for 1 week were also implanted
onto the latissimus dorsi muscle of athymic mice. Analysis
of tissue constructs retrieved 1–4 weeks postimplantation
showed that bioreactor-preconditioned constructs, but not
statically cultured control tissues, generated tetanic and twitch
contractile responses with a specific force of 1% and 10%,
respectively, of that observed on native latissimus dorsi.
Another kind of mechanical force, the pressure, was con-
sidered by Breuls et al. on their in vitro model system of
engineered skeletal muscle tissue constructs.71 With this
model system, the relationship between compressive tissue
straining and cell damage initiation was investigated under
well-defined environmental conditions. Compression of the
engineered muscle tissue constructs revealed that cell death
occurs within 1–2 h at clinically relevant straining percent-
ages and that higher strains led to earlier damage initiation.
In addition, the uniform distribution of dead cells through-
out the constructs suggested that sustained deformation of
the cells was the principal cause of cell death. For deter-
mining the tolerance of muscle cells to large mechanical
strains, Gefen et al.72 used a new experimental method of
determining the time-dependent critical compressive strains
for necrotic cell death in a planar tissue-engineered construct
under static loading. A half-spherical indentor was used to
induce a nonuniform, concentric distribution of strains in
the construct, and the data were calculated from the radius of
the damage region in the construct versus time. The author
regarded that was necessary for extrapolating biological
damage from muscle-strain data in biomechanical studies of
pressure ulcers and pressure-related deep tissue injury.
The key approach of developing a higher differentiated and
more functional skeletal muscle tissue is electrical stimulation,
which mimics the nerve stimulation during myogenesis, and
during regeneration of injured skeletal muscle, further, elec-
trically induced contractile activity promotes differentiation of
myotubes.73 Chronic electrical stimulation of primary rat cells
was shown to change the MHC expression with different
impulse patterns. Moreover, MHC expression during myo-
genesis can be modulated in vitro by electrical stimulation
in cell cultures that consist of predifferentiated skeletal mus-
cle cells.74 Using electrical stimulation, Dennis et al.22,23 and
Kosnik et al.67 analyzed their muscle tissue constructs,
Myooids, which produced a peak twitch force of approxima-
tely 320mN and a tetanic force of approximately 575mN when
stimulated electrically. Myooids also displayed many im-
portant functional similarities with adult skeletal muscle, in-
cluding positive force frequency, and normal length–tension
relationships. When the maximal twitch and tetanic forces
were normalized to cross-sectional area, Myooids produced a
specific force of 5–20 kN=m2, 2–8% of typical adult values or
5–30% of newborn muscles. The contractility of Myooids was
also similar to neonatal skeletal muscle with a time to peak
tension of approximately 60ms and a half relaxation time of
60–100ms. Further, mechanical force and electrical stimulation
were loaded on their rapidly generating 3D engineered mus-
cles using fibrin gel casting at the same time. Three weeks after
plating, the 3D engineered muscle generated a maximum
twitch force of 329 26.3mN and a maximal tetanic force of
805.8 55mN. The engineered muscles demonstrated normal
physiological function, including length–tension and force–
frequency relationships. Treatment with insulin-like growth
factor-I (IGF-I) resulted in a 50% increase in force production,
demonstrating that these muscles responded to hormonal in-
terventions.25 In 2008, Serena et al.75 investigated the effect of
exogenous electrical field, specifically designed to mimic part
of the neuronal activity, on MPCs cultured within 3D collagen
scaffolds. They showed that electric stimulation did not affect
cell viability and increased by 65.6% the release rate of NO(x),
an early molecular activator of satellite cells in vivo. NO(x)
release rate was decreased by an inhibitor of NO synthase,
both in stimulated and nonstimulated cultures, confirming
the endocrine origin of the measured NO(x). Importantly,
electrical stimulation also increased the expression of two
myogenic markers, MyoD and Desmin. Their findings indi-
cated that electrical stimulation could be a new strategy for
the effective 3D expansion of MPCs in vitro without losing
myogenic potential.
In addition, static magnetic field become a new interesting
for those who attempt to engineer functional skeletal muscle.
Coletti et al.76 indicated that static magnetic field can rescue of
muscle differentiation and enhance parallel orientation of L6
myotubes of engineered muscle tissue. For overcoming the
results of a uniform cell distribution only on the scaffold
surface adopting conventional static techniques, Gefen et al.
and Cimetta et al.77,78 invented a dynamic culture systems.
They designed and developed a perfusion bioreactor able to
ensure long-term culture conditions and uniform flow of
medium through 3D CS. A mathematical model to assist the
design of the experimental setup and of the operative condi-
tions was developed. Their results proved that the dynamic
culture conditions (3.5mL=min flow rate) improved cell via-
bility and lead to higher cell density and uniform distribution
throughout the entire 3D CS for both C2C12 and satellite cells.
Development of Other Skeletal
Muscle Tissue Constructing
Considering that innervation of in vitro generated muscle
tissue constructs has to be addressed to provide functional
muscle tissue in a clinical scenario, Bach et al.12,45,46 estab-
lished a coculture system with neuronal slices of the spinal
cord and myoblasts in a 3D fibrin matrix, and the results of
their study confirmed that a 3D environment and neuronal
tissue were required for the understanding of the control
mechanisms that were essential for in vitro regenerating
of highly differentiated skeletal muscle tissue. Meanwhile, a
3D nerve–muscle construct engineered by Larkin et al.79
displayed functional neuromuscular junctions and can be
electrically stimulated to contract via the neural extensions
projecting from the construct. Their immunohistochemical
labeling indicated that the junctions between the nerve ex-
tensions and the muscle constructs contained clusters of ace-
tylcholine receptors. Compared to muscles cultured without
nerve explants, constructs formed from nerve–muscle co-
culture showed spontaneous contractions with an increase
in frequency and force. Upon field stimulation, both twitch
(twofold) and tetanus (1.7-fold) were greater in the nerve–
muscle coculture system. Contractions could be elicited
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by electrically stimulating the neural extensions, although
smaller forces were produced than with field stimulation.
One of the major obstacles in engineering thick, complete
tissues is the need to vascularize the tissue in vitro, which could
maintain cell viability during tissue growth, induce structural
organization, and promote vascularization upon implantation.
Levenberg et al.80 induced endothelial vessel networks in en-
gineered skeletal muscle tissue constructs using a 3D multi-
culture system consisting of myoblasts, embryonic fibroblasts,
and endothelial cells coseeded on highly porous, biodegrad-
able polymer scaffolds. Huang et al.24,25 self-organized 3D en-
gineered muscle absenting of fibroblasts. Their results showed
that addition of embryonic fibroblasts increased the levels of
vascular endothelial growth factor expression in the construct
and promoted formation and stabilization of the endothelial
vessels. They also verified that prevascularization improved
the vascularization, bloodperfusion, andsurvival of themuscle
tissue constructs after transplantation.
Myoblast transplantation is a potentially useful thera-
peutic tool in muscle diseases, and the seeking of an efficient
micropatterned delivery system is developing. Boldrin et al.81
combined cell biology and polymer processing to create an
appropriate microenvironment for in vivo transplantation of
murine satellite cells. They prepared cells from single muscle
fibers derived from C57BL=6-Tgn–enhanced green fluores-
cent protein transgenic mice and seeded within a special
micropatterned PGA 3D scaffolds fabricated using soft li-
thography and thermal membrane lamination. They sug-
gested that implantation of cellularized scaffolds was better
than direct injection for delivering myogenic cells into re-
generating skeletal muscle. In 2008, they further proved that,
the micropatterned poly-lactic-glycolic acid 3D scaffolds
seeded within primary human MPCs were able to participate
in muscle regeneration, while scaffold-implanted muscles
contained a greater number of human nuclei, as revealed by
immunostaining and Western blot analyses, after implanting
in predamaged tibialis anterior muscles of CD1 nude mice.82
Nevertheless, Beier et al. explored the injectable skeletal
muscle. They injected expanded primary male myoblasts
into muscle defects in female syngeneic rats using a two-way
syringe (Duploject) within a 3D fibrin matrix. Detection and
evaluation were performed using Y chromosome in situ hy-
bridization, antidesmin immunostaining, and hematoxylin
and eosin staining. This injectable skeletal tissue obtained
well integration with host muscle fibers in a time-dependent
manner in their research.83
Muscle tissue engineering provides a model for under-
standing the development of the myotendinous junction.
The force exerted by a muscle must first be transmitted to the
endomysium, perimysium, and epimysium and then to the
tendon via the muscle–tendon interface or myotendinous
junction.84 To produce a strong connection between the col-
lagen fibers of the tendon and the actin filaments of the
muscle tissue, the myotendinous junction develops through
the deposition of a number of proteins that are important in
creating a tight connection between the intracellular and
ECM, such as laminin, integrin, vinculin, fibronectin, and
talin.84 Swasdison and Mayne85 were the first to realize that
the myotendinous junction could be modeled using en-
gineered muscle. Modifying the cell-sheet technique pio-
neered by Vandenburgh17, they showed that the muscle
fibers within their constructs formed attachments to the
outer layer of collagen and showed extensive invaginations
of the sarcolemma and surrounding basal lamina. Although
the invaginations suggested that they were forming a myo-
tendinous junction, direct insertions of the surrounding col-
lagen fibers into the basal lamina of the muscle fibers were
not observed.85 This issue had recently been explored more
thoroughly using self-organizing engineeredmuscles to show
that an immature myotendinous junction can be created
in vitro.86 Larkin et al.86 used sections of adult, fetal, or en-
gineered tendon in place of the sutures classically used as
anchors in the self-organized model. Although the diameter,
maximum isometric force, and specific force measurements
of the constructs were not different with tendon anchors,
when the constructs were subjected to physiological and
above physiological levels of strain during strain-to-failure
tests, the constructs failed in the muscle portion, thus re-
taining an intact muscle–tendon interface. Staining of the
constructs for paxillin, a focal adhesion protein thought to
be involved in mediating integrin adhesion at the myo-
tendinous junction, showed its presence in all three muscle–
tendon constructs. However, the expression of paxillin was
more diffuse in the engineered muscle–tendon constructs
than in the adult myotendinous junction, showing a pattern
more similar to the neonatal myotendinous region. This
suggested that the muscle–tendon constructs resembled an
immature myotendinous junction and can be used as a tool
to determine what was required for the development and
maturation of this understudied interface.
Patents Concerning with Skeletal Muscle Engineering
For recently published patents concerning with skeletal
muscle tissue engineering, most of them deal with different
kinds of scaffolds and new matrix materials. In U.S. Patent
20070202189,87 Ahlfors provided methods for producing an
acellular bioabsorbable structure that had biological regen-
erative properties (referred to hereafter as a ‘‘regeneration
matrix’’), which may be produced from any animal tissue,
including muscle. Their invention provided methods of ad-
ministering a regeneration matrix to a subject, wherein the
regeneration matrix initiated and=or increased tissue regen-
eration. Damaged tissue, such as nerve, muscle, liver, heart,
lung, and=or skin tissue, could be regenerated according to
methods of the invention includes. Such a regeneration ma-
trix may contain one or more of transferrin, serum albumin,
serum albumin precursor, complement component 3, chains
A–D hemoglobin, immunoglobulin M, immunoglobulin G1,
medullasin inhibitor 2, carbonic anhydrase, and=or cellulose
acetate 1 protein, and the regeneration matrix was supple-
mented with one or more therapeutic agents such as proteins,
peptides, drugs, cytokines, ECM molecules, and growth fac-
tors. This matrix can be seeded or mixed with cells, including
myoblast or muscle progenitor cells. The main producing
steps are isolating tissue sample, removing cells from the
tissue sample to generate an acellular sample, and incubat-
ing the acellular sample in an incubation chamber for the
formation of the acellular bioabsorbable tissue regenera-
tion matrix. At the same time, Van dyke et al. (U.S. Patent
20070248638)88 provided another kind of bioscaffold from
natural tissues by oxidizing a decellularized tissue to produce
a bioscaffold having pores therein. The pore size and porosity
were increased to better accommodate intact cells so that live
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cells can better infiltrate and inhabit the bioscaffold. The
bioscaffold may be freeze-dried or lyophilized, sterilized,
and (optionally) aseptically packaged for subsequent use. For
those who attempted to reconstruct skeletal muscle tissue
in vitro using acellular scaffolds, these patents were valuable
references. The tissue material and matrix, mentioned in U.S.
Patent 20060153797,89 was useful for promoting or facilitating
growth, development, and differentiation of cells and tissues.
More particularly, this invention provided a muscle-derived
material comprising intact or extracted ECM and=or cells
as well as cytokines, growth factors, and other components.
The muscle preparations of the present invention resembled
basement membrane and were derived from cellular-based
material. This scaffold can be prepared and used in vitro or
in vivo in muscle tissue engineering applications.
The ECM-based scaffolds retain the complex protein mix-
ture present in the original ECM. Hence, these scaffolds retain
functional cues necessary for organotypic differentiation of
the target tissues. Further, these scaffolds, alone or in combi-
nation with other (synthetic) polymers, provide good me-
chanical properties, which facilitate cell penetration and
proliferation within the scaffolds. Finally, the complex pro-
tein mix in these scaffolds contains also bioactive growth=
differentiation factors, which provide nutrition to support cell
growth even without serum. Thus, inventors explored this
field and have given some interesting products, such as inU.S.
Patent 20080213389.90 Lelkes et al. created 3D fibrous and
microporous scaffolds that retained the complexity of the in-
gredients and functionality of natural ECM. Electrospinning
and=or lyophilization techniques were adopted in this in-
vention. Both electrospun and lyophilized scaffolds were
suitable for skeletal muscle tissue engineering purposes.
Turos et al. called his invention as biocomposite (U.S. Pa-
tent 20080124371),91 which includes a biotic material, such
as collagen, and an abiotic material, such as ethylacrylate-
methylmethacrylate copolymer, or poly(acrylate-styrene) co-
polymer. Various polymeric nanoparticles and ratios of
polymer-to-biotic material (e.g., polymer-to-collagen) can be
utilized to alter the mechanical properties of the biocompo-
site. In another patent (U.S. Patent 20040037813),92 the elec-
troprocessed collagen compositions were taken as matrix
material and, together with cells, can be used in tissue en-
gineering field. Polymers such as poly lactic acid, PGA, co-
polymers of poly lactic acid and PGA, polycaprolactone,
poly ethylene-co-vinyl acetate, poly vinyl acetate, polyeth-
ylene glycol, and poly ethylene oxide can be involved in
these compositions. For tissue engineering scaffolds, the in-
ternal structure and the porosity will determine the func-
tional effects of different constructing tissues. Manufacturing
macroporous, biodegradable tissue engineering scaffoldswith
controlled pore interconnectivity and porosity is involved in
U.S. Patent 20040026811.93 On the other hand, many novel
scaffolds were used in muscle tissue engineering field and
patented—for example, the cellulose acetate thin, porous
membranes produced by electrospinning precursor polymer
solutions in acetone (U.S. Patent 20070275458)94; muscle
scaffolds included copolymers of a polyalkylene glycol and
an aromatic polyester in the form of a matrix (U.S. Patent
20020072798)95; and compositions and methods for pre-
paring electrospun matrices comprising at least one natural
biological material component and at least one synthetic
polymer material (U.S. Patent 20060204539).96 Associated
with the egress and activity of seeded cells, a scaffold that
was incorporated or was coated with a bioactive composition
and regulated the egress of resident cells spatially and tem-
porally was shown by Mooney et al. in their patent (U.S.
Patent 20080044900).97 This device regulated egress through
the physical or chemical characteristics of the scaffold itself.
The permeability of the scaffold composition was regulated
by selecting or engineering a material for greater or smaller
pore size, density, polymer cross linking, stiffness, tough-
ness, ductility, or viscoelasticity. The scaffold composition
contained physical channels or paths through which cells can
move more easily toward a targeted area of egress of the
device or of a compartment within the device. The scaffold
composition was optionally organized into compartments or
layers, each with a different permeability, so that the time
required for a cell to move through the device was precisely
and predictably controlled. Migration was also regulated by
the degradation, de- or rehydration, oxygenation, chemical
or pH alteration, or ongoing self-assembly of the scaffold
composition. These processes were driven by diffusion or cell
secretion of enzymes or other reactive chemicals.
Making engineered muscle without a scaffold and using
in implantation surgery were reported by Nakamura et al. in
their recent patent (U.S. Patent 20080004713).98 The invention
provided a synthetic tissue or complex that can be produced
by culture and had a high level of differentiation ability.
The present invention also provided a therapy for repairing
and=or regenerating tissue using replacement and covering.
By culturing cells under specific culture conditions such that
medium contains an ECM synthesis promoting agent, the
cells were organized and were easily detached from a culture
dish. In addition, the self-contraction of the tissue can be
regulated by culturing the tissue in a suspended manner.
Therefore, it was possible to regulate the 3D shape of the
tissue. Kosnik et al. developed this 3D connective tissue
construct in their patent (U.S. Patent 20080199953)99 and
used it extensively in skeletal muscle engineering field.
A critical procedure while engineering skeletal muscle is to
generate multiple layers of skeletal muscle that are oriented in
the same direction. The invention of Tresco et al. (U.S. Patent
20060140918)100 related to a bioartificial composite comprised
of a substrate having at least one surface capable of the re-
ception and growth promoting retention of a cellular prepa-
ration, and a first layer of adherent cells disposed on said
surface. The first layer was prepared from the cellular prep-
aration, and the cells comprising the first layer had cytoskel-
etal elements aligned uniformly, so that the bioartificial
composite acted as a template to accept a second layer of
cells upon the first layer. The device may be implanted for
the promotion of muscle tissue regrowth. The 3D multilayer
device serving as the template for cell adhesion and growth
was also mentioned in Borenstein et al. patent (U.S. Patent
7371400).101 Yost et al. invented the aligned biopolymer scaf-
fold for use in muscle tissue engineering and the other ap-
plications. Their invention was directed to a novel tubular
tissue scaffold comprising a tube having a wall, wherein the
wall included biopolymer fibrils that were aligned in a helical
pattern around the longitudinal axis of the tube where the
pitch of the helical pattern changed with the radial position
in the tube wall. The scaffold was capable of directing the
morphological pattern of attached and growing cells to form a
helical pattern around the tube walls.102,103
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During the development of the skeletal muscle engineer-
ing, the delicate construction devices, including different
bioreactors, appear more simple and convenient to operate.
The bioreactor of Hutmacher et al. comprised a chamber for
containing cells or tissue cultures within a culture medium, a
detector capable of detecting a change in one or more me-
tabolites associated with growth of the cell or tissue cultures
within the chamber, and a chamber drive capable of rotating
the chamber at a first speed about a first axis and a second
speed about a second axis, the second axis being disposed
at an angle relative to the first axis. In use, the magnitudes
of the first speed and the second speed were independently
variable to each other (U.S. Patent 20060019388).104 Yoo
et al.’s bioreactor was supplemented with a stretching and
relaxing device, for enhancing the functionality of the muscle
tissue formed on the bioreactor from the precursor muscle
cells (U.S. Patent 20060239981).105 During 2003 and 2004,
Bowlin et al.106,107 invented and published patents aiming
exclusively at skeletal muscle tissue engineering. The pro-
duction of them included an ECM, tendon, and muscle cells.
The ECM was made of a matrix of electrospun polymer
fibers. The tendon was made of extruded collagen fibers,
and the muscle cells were disposed on the ECM in such a
manner that the combination of components will function-
ally and structurally acted as normal muscle tissue. Vein’s
invention was prospective: they invented a nonhuman tis-
sue-engineered meat product and a method for producing
such meat product. The meat product comprised muscle cells
that are grown ex vivo and was used for food consumption.
The meat product may also comprise other cells such as fat
cells or cartilage cells, or both, that were grown ex vivo to-
gether with the muscle cells (U.S. Patent 20050084958).108
Future Perspectives and Conclusion
Tissue engineering and regenerative medicine is an exiting
interdisciplinary field that applies the principles of engi-
neering and biology to the development of viable substitutes
that restore the function of damaged tissues and organs.
Skeletal muscle tissue engineering has developed rapidly
over the last 20 years. With the development of simple and
standardized machines in the next 2–3 years, it will be pos-
sible for anyone to use tissue-engineered muscle to deter-
mine how exercise affects muscle physiology, turn on or off
any gene and determine the resulting effect on muscle
function quickly and inexpensively, provide an inexpensive
screening process before more costly and time-consuming
muscle-specific transgenic animals are created, screen in-
hibitor compounds to determine which molecular signaling
pathways are required for muscle adaptation to exercise, and
offer researchers a powerful tool to rapidly screen hundreds
of genes=drugs for their ability to alter tissue function.
Growing new tissues (neoorganogenesis) is a complex
process that requires the teamwork of developmental and
cellular molecular biologists, engineers, material scientists,
and physicians. As the techniques of tissue engineering be-
come more sophisticated, the usefulness of these methods for
supporting the possibilities of reconstructive surgery will
hopefully become a reality. Future developments and the
decision regarding which approach is more promising de-
pend on the elucidation of the relationships among cell
growth and differentiation, the 3D environment, the archi-
tecture of the cells, and gene expression of the developmental
process and the survival of the cells and integration in the
host in in vivo experiments. As the techniques of tissue en-
gineering become more sophisticated and as issues such as
vascularization and innervation are addressed, the useful-
ness of these methods for reconstructive surgery may grow
significantly.
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